The $110M upfront strengthens HUTCHMED's balance sheet and validates its ATTC platform. Monitor for Phase Ia data readouts and any GSK-initiated Phase II starts, which would trigger additional milestones. The deal structure (HUTCHMED retains China rights) preserves upside in the largest oncology market.
Price Chart
Executive Summary
HUTCHMED closed the exclusive license agreement with GSK for HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted therapy conjugate (ATTC), granting GSK worldwide rights outside China. HUTCHMED expects to receive a $110 million upfront payment shortly, with potential milestone payments up to $1.185 billion and tiered royalties. This de-risks the asset's global development and provides near-term cash, while HUTCHMED retains China rights and Phase I responsibilities.
Key Facts
- License agreement closed with GSK for HMPL-A830, a KRAS-EGFR ATTC drug candidate
- GSK gets worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan
- HUTCHMED expects $110 million upfront payment shortly
- Potential milestone payments up to $1.185 billion plus tiered royalties
- Phase Ia global trial initiated September 2026 in China and US
- HUTCHMED responsible for global Phase I; GSK for subsequent development and commercialization
Financial Impact
$110 million upfront cash inflow; up to $1.185 billion in milestones; tiered royalties on net sales
Risk Factors
- HMPL-A830 is early-stage (Phase Ia just initiated); clinical failure risk remains high
- Milestone payments are contingent on development and regulatory success
- GSK may deprioritize the program, delaying milestones
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001648257-26-000066 |
| Document: hcm-20261021x6k.htm | 0001648257-26-000066 |
| Document: 0001648257-26-000066-index-headers.html | 0001648257-26-000066 |
| Document: 0001648257-26-000066-index.html | 0001648257-26-000066 |
| Document: 0001648257-26-000066.txt | 0001648257-26-000066 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $14.34 | awaiting T+20 | — | $13.73 (−4.29%) |
Oct 26, 2026 1d ago | 6-K | $15.41 | awaiting T+20 | — | $13.73 (−10.93%) |
Oct 26, 2026 1d ago | Press Release | $14.50 | awaiting T+20 | — | $13.73 (−5.34%) |
Oct 26, 2026 1d ago | Press Release | $14.34 | awaiting T+20 | — | $13.73 (−4.29%) |
Oct 21, 2026 6d ago | 6-K | $14.37 | awaiting T+20 | — | $13.73 (−4.49%) |
Sep 29, 2026 28d ago | 6-K | $14.15 | awaiting T+20 | — | $13.73 (−3.00%) |
Sep 28, 2026 28d ago | 6-K | $14.15 | awaiting T+20 | — | $13.73 (−3.00%) |
Sep 29, 2026 28d ago | Press Release | $14.63 | awaiting T+20 | — | $13.73 (−6.19%) |
Sep 24, 2026 4w ago | 6-K | $13.90 $14.28 | ▲ +2.73% | ▲ +3.15% | $13.73 (−1.26%) |
Sep 24, 2026 4w ago | Press Release | $13.94 $14.36 | ▲ +3.01% | ▲ +4.49% | $13.73 (−1.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers